• Publications
  • Influence
Dual time-point FDG PET-CT for differentiating benign from malignant solitary pulmonary nodules in a TB endemic area.
OBJECTIVE Fluorodeoxyglucose (FDG)-positron emission tomography (PET) is an accurate non-invasive imaging test for differentiating benign from malignant solitary pulmonary nodules (SPNs). We aimed toExpand
Advances in imaging of tuberculosis: the role of 18F-FDG PET and PET/CT
Purpose of review To review the main applications, advantages and limitations of 18F-FDG PET and PET/computed tomography (CT), and some other tracers in imaging of tuberculosis (TB). Recent findingsExpand
68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients
BackgroundTo report on imaging findings using 68Ga-PSMA-HBED-CC PET in a series of 19 breast carcinoma patients.Methods68Ga-PSMA-HBED-CC PET imaging results obtained were compared to routinelyExpand
Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours
Data available in patients suffering from squamous cell carcinoma of the head and neck, lung carcinoma, oesophageal carcinoma and gynaecological malignancies suggest that metabolic tumour volume andExpand
Extraordinary arousal from semi-comatose state on zolpidem. A case report.
A young semi-comatose male patient was investigated using 99mTc hexamethyl-propylene amine oxime (99mTc HMPAO) brain single photon emission computed tomography (SPECT) before and after administrationExpand
Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy
Metastatic prostate carcinoma overexpresses prostate-specific membrane antigen (PSMA), making this antigen a suitable target for radioligand therapy of the disease. Here we report on our experienceExpand
Impact of 68Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management
The objective of this study was to assess the impact of 68Ga-prostate-specific membrane antigen (68Ga-PSMA) PET/CT on the management of prostate cancer in patients with biochemical recurrence (BCR).Expand
213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
Prostate-specific membrane antigen radioligand therapy (PSMA-RLT) with Lu-PSMA holds great promise as a safe treatment option in patients with metastasized castration-resistant prostate cancerExpand
Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study
The introduction of 18F-labeled prostate-specific membrane antigen (PSMA)–targeted PET/CT tracers, first 18F-DCFPyLExpand
Antimicrobial Peptides: Their Role as Infection-Selective Tracers for Molecular Imaging
Antimicrobial peptides (AMPs) are a heterogeneous class of compounds found in a variety of organisms including humans and, so far, hundreds of these structures have been isolated and characterised.Expand